In This Article:
“Sell in May and go away” is a common adage in investing. It’s based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines. While timing the market is sketchy work at best, following the herd might be the best option for some investors.
All that’s left is figuring out if you’re holding prime stocks to sell. So, I’ve developed a list of companies that might get the short stick in May based on these criteria.
-
Trade above their mean target price
-
Have a hold to strong sell rating from analysts
Then, I sorted them based on the highest percentage difference from the stock’s mean target price. This lets me focus on stocks that are too far from their fair price, according to analyst estimates.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
GameStop Corp (GME)
Source: 1take1shot / Shutterstock.com
If you grew up as a gamer, you’d have heard of GameStop Corp (NYSE:GME). The company sells video games and related products via its e-commerce platform and local stores.
Gamestop operates in more than 4000 stores across the United States, Canada, Australia and Europe. In addition to video games, the company offers print and digital gaming publications, gadgets, electronics, collectibles and toys.
GME experienced a massive price surge in 2021, primarily thanks to investors from r/wallstreetbets on Reddit. This herd mentality forced other institutional buyers to cover their positions, leading to a short squeeze and significant losses.
As a result, investors now see GameStop as a meme stock. Once Keith Hill, more commonly known as Roaring Kitty, posted about GME in May 2024 after nearly four years, the stock peaked at over $60 and now trades at $18.83.
However, analysts estimate that GME has only a $7 target price. This means GME stock still trades way above its target price. Analysts covering GameStop warn that it is one of the most clear-cut stocks to sell right now, as the company presents a significant short-term sell-off risk.
Synlogic (SYBX)
Source: shutterstock.com/Romix Image
Biopharmaceutical company Synlogic (NASDAQ:SYBX) aims to transform the care for various diseases. Synlogic boasts pipeline products aimed at treating diseases like gout, hyperoxaluria and cystinuria. It leads by its proprietary approach of creating oral medicines with new enzymatic pathways built to produce or consume its specific biological targets.
Synlogic’s fiscal year 2023 financials saw revenue and EPS improvements. Notably, the top line grew from $1.18 million to $3.37 million, an almost 200% increase. However, some glaring issues dampen this otherwise good news.